Disclosed is use of β-nicotinamide mononucleotide in the preparation of anti-aging drugs or health-care products. A single dose of the β-nicotinamide mononucleotide is 1-500 mg/Kg body weight/day, and the drug or health-care product is in the form of tablets, capsules, granules, aqueous solutions, enteric-coated preparations or injections.